Summary table PNG.PNG (90.65 kB)
Epi proColon® for Colorectal Cancer Screening: A Profile of Its Use in the USA
online resource
posted on 2020-06-19, 00:04 authored by Matt ShirleyCompliance with Ethical Standards
Funding The preparation of this review was not supported by any external funding.
Conflicts of interest Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.Additional
information about this Adis Diagnostic Q&A article can be found here.
Abstract
Epi proColon® is a blood-based
colorectal cancer (CRC) screening test that presents a convenient, non-invasive
option for CRC screening in average-risk adults aged ≥ 50 years who are otherwise non-compliant
to guideline-recommended screening programs. The Epi proColon test involves the
use of a real-time PCR assay to detect methylated Sept9 DNA (a biomarker for CRC) in plasma derived from a whole
blood sample. Epi proColon generally performed well in prospective clinical
trials, having non-inferior sensitivity for detecting CRC compared with a fecal
immunochemical test (FIT). Microsimulation modeling supports annual Epi
proColon testing, as for FIT. Although the Epi proColon test specificity is
lower than that of a FIT, the Epi proColon test may be useful for improving
participation and compliance in CRC screening, as evidenced in a small
randomized controlled clinical trial which showed that uptake of an offer of an
Epi proColon blood test was significantly higher than that for a FIT in
subjects who were overdue for CRC screening.
© Springer Nature Switzerland AG 2020
